Brief: Sinomab Bioscience Gets Ind Application For Sm03 (Suciraslimab) For Treatment Of Alzheimer
15/11/2023 15:27
Nov 15 (Reuters) - SinoMab BioScience Ltd 3681.HK :
* IND APPLICATION FOR SM03 (SUCIRASLIMAB) FOR TREATMENT OF
ALZHEIMER'S DISEASE ACCEPTED BY NMPA OF CHINA
Further company coverage: 3681.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sinomab Bioscience
See all newsBrief: Sinomab Bioscience Posts HY Loss Of RMB127.4 Million
Brief: Sinomab Bioscience Says Fang Liang Resigns As Executive Director
Brief: Sinomab Bioscience Announces Major Deal For Disposal Of Suzhou Property And Facility For RMB280 MLN
Brief: SinoMab Bioscience Appoints Fang Liang As Executive Director
Brief: Hainan Haiyao Plans To Unload Stake In Sinomab Bioscience